Журнал "Почки" том 9, №1

Îãëÿä / Review
33. Vargas H.A., Kramer G.M., Scott A.M. et al. Reproducibility
and repeatability of semiquantitative18F-fluorodihydrotestosterone
uptake metrics in castration-resistant prostate cancer metastases: a
prospective multicenter study. J. Nucl. Med. 2018. 59. Р. 1516-1523.
DOI: 10.2967/jnumed.117.206490. Epub 2018 Apr 6.
34. Eiber M., Weirich G., Holzapfel K. et al. Simultaneous 68Ga-
PSMA HBED-CC PET/MRI improves the localization of primary
prostate cancer. Eur. Urol. 2016. 70. Р. 829-836. DOI: 10.1016/j.
eururo.2015.12.053. Epub 2016 Jan 18.
35. Hicks R.M., Simko J.P., Westphalen A.C. et al. Diagnostic
accuracy of 68Ga-PSMA-11 PET/MRI compared with multiparametric
MRI in the detection of prostate cancer. Radiology. 2018. 289.
Р. 730-737. DOI: 10.1148/radiol.2018180788. Epub 2018 Sep 18.
36. Turkbey B., Mani H., Shah V. et al. Multiparametric 3T
prostate magnetic resonance imaging to detect cancer: histopathological
correlation using prostatectomy specimens processed in customized
magnetic resonance imaging based molds. J. Urol. 2011. 186. Р. 1818-
1824. DOI: 10.1016/j.juro.2011.07.013. Epub 2011 Sep 25.
37. Weinreb J.C., Barentsz J.O., Choyke P.L. et al. PI-RADS
prostate imaging: reporting and data system-2015, version 2. Eur.
Urol. 2016. 69. Р. 16-40. DOI: 10.1016/j.eururo.2015.08.052. Epub
2015 Oct 1.
38. Ahmed H.U., El-Shater Bosaily A., Brown L.C. et al. Diagnostic
accuracy of multiparametric MRI and TRUS biopsy in prostate
cancer (PROMIS): a paired validating confirmatory study. Lancet.
2017. 389. Р. 815-822. DOI: 10.1016/S0140-6736(16)32401-1.
Epub 2017 Jan 20.
39. Moldovan P.C., Van den Broeck T., Sylvester R. et al. What
is the negative predictive value of multiparametric magnetic resonance
imaging in excluding prostate cancer at biopsy? A systematic review
and meta-analysis from the European Association of Urology Prostate
Cancer Guidelines Panel. Eur. Urol. 2017. 72. Р. 250-266. DOI:
10.1016/j.eururo.2017.02.026. Epub 2017 Mar 21.
40. Mohammadian Bajgiran A., Afshari Mirak S., Shakeri S.
et al. Characteristics of missed prostate cancer lesions on 3T multiparametric-MRI
in 518 patients: based on PI-RADSv2 and using
whole-mount histopathology reference. Abdom. Radiol. (NY). 2019.
44. Р. 1052-1061. DOI: 10.1007/s00261-018-1823-6.
41. Borofsky S., George A.K., Gaur S. et al. What are we missing?
False-negative cancers at multiparametric MR imaging of the prostate.
Radiology. 2018. 286. Р. 186-195. DOI: 10.1148/radiol.2017152877.
Epub 2017 Oct 20.
42. Sala E., Akin O., Moskowitz C.S. et al. Endorectal MR imaging
in the evaluation of seminal vesicle invasion: diagnostic accuracy
and multivariate feature analysis. Radiology. 2006. 238. Р. 929-937.
DOI: 10.1148/radiol.2383050657.
43. de Rooij M., Hamoen E.H., Witjes J.A. et al. Accuracy of magnetic
resonance imaging for local staging of prostate cancer: a diagnostic
metaanalysis. Eur. Urol. 2016. 70. Р. 233-245. DOI: 10.1016/j.
eururo.2015.07.029. Epub 2015 Jul 26.
44. Mühlematter U.J., Becker K.S.A., Müller J. et al. Detection
of extracapsular extension in high risk prostate cancer patients: multiparametric
MRI vs.68Ga-PSMA-11 PET/MRI. Paper presented at:
2019 European Congress of Radiology; February 28, 2019; Vienna,
Austria.
45. Ross H.M., Kryvenko O.N., Cowan J.E. et al. Do adenocarcinomas
of the prostate with Gleason score (GS) #6 have the potential
to metastasize to lymph nodes? Am. J. Surg. Pathol. 2012. 36. Р. 1346-
1352. DOI: 10.1097/PAS.0b013e3182556dcd.
46. Briganti A., Larcher A., Abdollah F. et al. Updated nomogram
predicting lymph node invasion in patients with prostate cancer undergoing
extended pelvic lymph node dissection: the essential importance
of percentage of positive cores. Eur. Urol. 2012. 61. Р. 480-487. DOI:
10.1016/j.eururo.2011.10.044. Epub 2011 Nov 7.
47. Eggener S.E., Scardino P.T., Walsh P.C. et al. Predicting
15-year prostate cancer specific mortality after radical prostatectomy.
J. Urol. 2011. 185. Р. 869-875. DOI: 10.1016/j.juro.2010.10.057.
Epub 2011 Jan 15.
48. Hövels A.M., Heesakkers R.A.M., Adang E.M. et al. The
diagnostic accuracy of CT and MRI in the staging of pelvic lymph
nodes in patients with prostate cancer: a meta-analysis. Clin. Radiol.
2008. 63. Р. 387-395. DOI: 10.1016/j.crad.2007.05.022. Epub 2008
Feb 4.
49. Evangelista L., Guttilla A., Zattoni F. et al. Utility of choline
positron emission tomography/computed tomography for lymph node
involvement identification in intermediate- to high-risk prostate cancer:
a systematic literature review and meta-analysis. Eur. Urol. 2013.
63. Р. 1040-1048. DOI: 10.1016/j.eururo.2012.09.039. Epub 2012
Sep 25.
50. Hofman M.S., Murphy D.G., Williams S.G. et al. A prospective
randomized multicentre study of the impact of gallium-68 prostate-specific
membrane antigen (PSMA) PET/CT imaging for staging
high-risk prostate cancer prior to curative-intent surgery or radiotherapy
(proPSMA study): clinical trial protocol. BJU Int. 2018. 122.
Р. 783-793. DOI: 10.1111/bju.14374. Epub 2018 Jun 3.
51. Selnæs K.M., Kruger-Stokke B., Elschot M. et al. 18F-fluciclovine
PET/MRI for preoperative lymph node staging in high-risk
prostate cancer patients. Eur. Radiol. 2018. 28. Р. 3151-3159. DOI:
10.1007/s00330-017-5213-1. Epub 2018 Jan 2.
52. Grubmüller B., Baltzer P., Hartenbach S. et al. PSMA ligand
PET/MRI for primary prostate cancer: staging performance
and clinical impact. Clin. Cancer Res. 2018. 24. Р. 6300-6307. DOI:
10.1158/1078-0432.CCR-18-0768. Epub 2018 Aug 23.
53. Giesel F.L., Fiedler H., Stefanova M. et al. PSMA PET/CT
with Glu-urea-Lys-(Ahx)-[68Ga(HBED-CC)] versus 3D CT volumetric
lymph node assessment in recurrent prostate cancer. Eur. J.
Nucl. Med. Mol. Imaging. 2015. 42. Р. 1794-1800. DOI: 10.1007/
s00259-015-3106-6. Epub 2015 Jul 11.
54. Maurer T., Gschwend J.E., Rauscher I. et al. Diagnostic efficacy
of 68 gallium-PSMA positron emission tomography compared
to conventional imaging for lymph node staging of 130 consecutive
patients with intermediate to high risk prostate cancer. J. Urol. 2016.
195. Р. 1436-1443. DOI: 10.1007/s00259-015-3106-6. Epub 2015
Jul 11.
55. Scher H.I., Morris M.J., Stadler W.M. et al. Trial design
and objectives for castration-resistant prostate cancer: updated recommendations
from the Prostate Cancer Clinical Trials Working
Group 3. J. Clin. Oncol. 2016. 34. Р. 1402-1418. DOI: 10.1200/
JCO.2015.64.2702. Epub 2016 Feb 22.
56. Sweeney C.J., Chen Y.H., Carducci M. et al. Chemohormonal
therapy in metastatic hormone-sensitive prostate cancer. N. Engl.
J. Med. 2015. 373. Р. 737-746. DOI: 10.1056/NEJMoa1503747.
57. Pyka T., Okamoto S., Dahlbender M. et al. Comparison of
bone scintigraphy and 68Ga-PSMA PET for skeletal staging in prostate
cancer. Eur. J. Nucl. Med. MolImaging. 2016. 43. Р. 2114-2121.
DOI: 10.1007/s00259-016-3435-0.
58. Mottet N., Bellmunt J., Bolla M. et al. EAU-ESTRO-SIOG
guidelines on prostate cancer. Part 1: screening, diagnosis, and local
Òîì 9, ¹ 1, 2020
www.mif-ua.com, http://kidneys.zaslavsky.com.ua 95